natgillin/translations-raw huggingface dataset:
In the All ACS population, prasugrel was associated with a lower incidence of CV death, non-fatal MI, or non-fatal stroke compared to clopidogrel, regardless of baseline characteristics such as age, sex, body weight, geographical region, use of GP IIb/IIIa inhibitors, and stent type. 
U populaciji svih bolesnika s ACS-om primjena prasugrela je u usporedbi s primjenom klopidogrela bila povezana s nižom incidencijom smrti zbog KV uzroka, nesmrtonosnog IM odnosno nesmrtonosnog moždanog udara, bez obzira na početne karakteristike poput dobi, spola, tjelesne težine, geografske regije, primjene inhibitora GP IIb/IIIa ili vrstu stenta.
What you need to know before you take Prasugrel Mylan 
Što morate znati prije nego počnete uzimati Prasugrel Mylan
Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4 and CYP3A5, did not affect prasugrel-mediated inhibition of platelet aggregation or the prasugrel active metabolite's AUC and Tmax, but decreased the Cmax by 34% to 46%. 
Ketokonazol (400 mg na dan), selektivan i snažan inhibitor CYP3A4 i CYP3A5, nije utjecao na prasugrelom posredovanu inhibiciju agregacije trombocita niti na AUC i Tmax aktivnog metabolita prasugrela, ali je smanjio njegov Cmax za 34% do 46%.
Higher inhibition of platelet aggregation was observed in patients switched to prasugrel 10 mg compared with those treated with clopidogrel 150 mg. 
Veća inhibicija agregacije trombocita primijećena je u bolesnika prebačenih na prasugrel u dozi od 10 mg u odnosu na one liječene klopidogrelom u dozi od 150 mg.
Titanium dioxide (E171) 
Film ovojnica poli(vinilni alkohol) talk titanijev dioksid (E171)
• Bleeding from your rectum, blood in your stools or black stools 
• krvarenje iz završnog dijela debelog crijeva, krv u stolici ili crnu stolicu
The use of Prasugrel Mylan in patients ≥75 years of age is generally not recommended and should only be undertaken with caution after a careful individual benefit/risk evaluation by the prescribing physician indicates that benefits in terms of prevention of ischaemic events outweigh the risk of serious bleedings. 
Primjena lijeka Prasugrel Mylan u bolesnika u dobi od ≥ 75 godina općenito se ne preporučuje i smije se provoditi uz oprez tek nakon što liječnik propisivač pažljivo procijeni korist i rizik u pojedinog bolesnika i zaključi da dobrobit u smislu prevencije ishemijskih događaja nadilazi rizik od ozbiljnih krvarenja.
Prasugrel Mylan is contraindicated in patients with severe hepatic impairment (Child Pugh class C). 
Prasugrel Mylan je kontraindiciran u bolesnika s teškim oštećenjem jetre (Child-Pugh stadij C).
Prasugrel has no or negligible influence on the ability to drive and use machines. 
Prasugrel ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Prasugrel Mylan is to be administered concomitantly with acetylsalicylic acid (ASA). 
Prasugrel Mylan se mora primjenjivati zajedno s acetilsalicilatnom kiselinom (ASK).
Therefore, CYP3A inhibitors such as azol antifungals, HIV protease inhibitors, clarithromycin, telithromycin, verapamil, diltiazem, indinavir, ciprofloxacin, and grapefruit juice are not anticipated to have a significant effect on the pharmacokinetics of the active metabolite. 
Stoga se ne predviđa da bi inhibitori CYP3A4 poput azolnih antimikotika, inhibitora HIV proteaze, klaritromicina, telitromicina, verapamila, diltiazema, indinavira, ciprofloksacina ili soka od grejpa imali značajan učinak na farmakokinetiku aktivnog metabolita.
Pharmacokinetics of prasugrel and its inhibition of platelet aggregation are similar in patients with moderate renal impairment (GFR 30<50 ml/min/1.73 m²) and healthy subjects. 
Farmakokinetika prasugrela i njegova inhibicija agregacije trombocita podjednake su u ispitanika s umjerenim oštećenjem bubrega (brzina glomerularne filtracije 30 < 50 ml/min/1,73 m²) i zdravih ispitanika.
For patients who received their last dose of thienopyridine within 4 to 7 days prior to CABG, the frequencies decreased to 11.3% (9 of 80 patients) in the prasugrel group and 3.4% (3 of 89 patients) in the clopidogrel group. 
Među bolesnicima koji su primili posljednju dozu tienopiridina u roku od 4 do 7 dana prije CABG-a, učestalost se smanjila na 11,3% (9 od 80 bolesnika) u skupini koja je primala prasugrel, odnosno na 3,4% (3 od 89 bolesnika) u skupini koja je primala klopidogrel.
In healthy subjects, patients with stable atherosclerosis, and patients with ACS receiving prasugrel, there was no relevant effect of genetic variation in CYP3A5, CYP2B6, CYP2C9, or CYP2C19 on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation. 
U zdravih ispitanika, bolesnika sa stabilnom aterosklerozom i bolesnika s ACS-om koji su primali prasugrel nisu zabilježeni značajni učinci genetskih varijacija na CYP3A5, CYP2B6, CYP2C9 ili CYP2C19 na farmakokinetiku prasugrela odnosno na njegov učinak na inhibiciju agregacije trombocita.
Although bleeding was increased with prasugrel, an analysis of the composite endpoint of death from any cause, nonfatal myocardial infarction, nonfatal stroke, and non-CABG-related TIMI major haemorrhage favoured prasugrel compared to clopidogrel (Hazard ratio, 0.87; 95% CI, 0.79 to 0.95; p=0.004). 
Iako je broj krvarenja bio povećan uz primjenu prasugrela, rezultati analize objedinjenih ishoda koji su uključivali smrt zbog bilo kojeg uzroka, nesmrtonosni infarkt miokarda, nesmrtonosni moždani udar i značajno krvarenje (prema TIMI) nevezano uz CABG govorili su u prilog prasugrela u usporedbi s klopidogrelom (HR: 0,87; 95% CI: 0,79 do 0,95; p = 0,004).
A 5 mg maintenance dose should be used. 
Mora se primjenjivati doza održavanja od 5 mg.
Prasugrel Mylan reduces the chances of you having a further heart attack or stroke or of dying from one of these atherothrombotic events. 
Prasugrel Mylan smanjuje vjerojatnost ponovnog srčanog udara, moždanog udara ili smrti kao posljedice nekog od tih aterotrombotskih događaja.
Table 2 summarises haemorrhagic and non-haemorrhagic adverse reactions in TRITON, or that were spontaneously reported, classified by frequency and system organ class. 
Tablici 2 su sažeto prikazane hemoragijske i nehemoragijske nuspojave u ispitivanju TRITON ili iz spontanih prijava, klasificirane prema učestalosti i klasifikaciji organskih sustava.
Study TADO teste the use of prasugrel (n=171) vs placebo (n=170) in patients, ages 2 to less than 18 years of age, with sickle cell anaemia for reduction of vaso occlusive crisis in a phase III study. 
Ispitivanje TADO bilo je ispitivanje faze III u kojem se ispitivala primjena prasugrela (n = 171) naspram placeba (n = 170) za smanjenje vazookluzivne krize u bolesnika s anemijom srpastih stanica u dobi od 2 do manje od 18 godina.
You should show the doctor your pack of Prasugrel Mylan. 
Pokažite liječniku pakiranje lijeka Prasugrel Mylan.
Concomitant administration of Prasugrel Mylan with coumarin derivatives other than warfarin has not been studied. 
Nije ispitivana istodobna primjena lijeka Prasugrel Mylan s derivatima kumarina osim varfarina.
Patients ≥75 years of age have greater sensitivity to bleeding and higher exposure to the active metabolite of prasugrel (see sections 4.4, 4.8, 5.1 and 5.2). 
Bolesnici u dobi od ≥ 75 godina skloniji su krvarenju i izloženi su većoj koncentraciji aktivnog metabolita prasugrela (vidjeti dijelove 4.4, 4.8, 5.1 i 5.2).
Therefore, prasugrel can be administered without regard to food; however, the administration of prasugrel loading dose in the fasted state may provide most rapid onset of action (see section 4.2). 
Stoga se prasugrel može davati neovisno o obroku, no primjena udarne doze prasugrela natašte može omogućiti najbrži nastup djelovanja (vidjeti dio 4.2).
Following administration of 75 mg clopidogrel once daily for 10 days, 40 healthy subjects were switched to prasugrel 10 mg once daily with or without a loading dose of 60 mg. 
Nakon primjene klopidogrela u dozi od 75 mg jedanput na dan tijekom 10 dana, 40 zdravih ispitanika prebačeno je na prasugrel u dozi od 10 mg jedanput na dan, s udarnom dozom od 60 mg ili bez nje.
Results of a pharmacodynamic/pharmacogenomic study in 720 Asian ACS PCI patients demonstrated that higher levels of platelet inhibition are achieved with prasugrel compared to clopidogrel, and that prasugrel 60 mg loading dose/10 mg maintenance dose is an appropriate dose regimen in Asian subjects who weigh at least 60 kg and are less than 75 years of age (see section 4.2). 
Rezultati farmakodinamičkih/farmakogenomskih ispitivanja provedenih na 720 bolesnika azijskog podrijetla s ACS-om podvrgnutih PCI-ju pokazali su da prasugrel dovodi do višeg stupnja inhibicije trombocita nego klopidogrel te da udarna doza prasugrela od 60 mg i doza održavanja od 10 mg predstavlja primjeren režim doziranja za bolesnike azijskog podrijetla koji imaju najmanje 60 kg i mlađi su od 75 godina (vidjeti dio 4.2).
This is due to an increase in exposure to the active metabolite of prasugrel, and an increased risk of bleeding in patients with body weight <60 kg when given a 10 mg once daily dose compared with patients ≥60 kg (see sections 4.4, 4.8 and 
Razlog tomu je povećana izloženost aktivnom metabolitu prasugrela i povećan rizik od krvarenja nakon primjene doze od 10 mg na dan u bolesnika tjelesne težine < 60 kg u usporedbi s bolesnicima tjelesne težine ≥ 60 kg (vidjeti dijelove 4.4, 4,8 i 5.2).
Prasugrel Mylan, which contains the active substance prasugrel, belongs to a group of medicines called antiplatelet agents. 
Prasugrel Mylan, koji sadrži djelatnu tvar prasugrel, pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
Effects of Prasugrel Mylan on other medicinal products 
Učinci lijeka Prasugrel Mylan na druge lijekove
Prasugrel had no effect on fertility of male and female rats at oral doses up to an exposure 240 times the recommended daily human maintenance dose (based on mg/m²). 
Prasugrel nije utjecao na plodnost mužjaka i ženki štakora koji su primali peroralne doze do izloženosti 240 puta veće od one u ljudi uz primjenu preporučene dnevne doze održavanja (na temelju mg/m²).
In the phase 3 clinical trial, prasugrel was administered without regard to co administration of a proton pump inhibitor or H2 blocker. 
U fazi III kliničkog ispitivanja prasugrel se primjenjivao bez obzira na istodobnu primjenu inhibitora protonske pumpe ili blokatora H2 receptora.
If you forget your dose for an entire day, just resume taking Prasugrel Mylan at its usual dose the next day. 
Ako niste uzeli Prasugrel Mylan tijekom cijelog dana, samo nastavite s uobičajenom dozom sljedećeg dana.
More than 98% of subjects had ≥20% inhibition of platelet aggregation during maintenance dosing. 
U više od 98% ispitanika je tijekom primjene doze održavanja postignuta inhibicija agregacije trombocita od ≥ 20%.
The observed benefit of prasugrel in patients ≥75 years was less than that observed in patients <75 years. 
Korist liječenja prasugrelom u bolesnika u dobi od ≥ 75 godina bila je manja od one u bolesnika mlađih od 75 godina.
Patients ≥75 years were at increased risk of bleeding, including fatal (see sections 4.2, 4.4, and 4.8). 
Bolesnici u dobi od ≥ 75 godina imali su povećan rizik od krvarenja, uključujući i ona smrtonosna (vidjeti dijelove 4.2, 4.4 i 4.8).
Table 2: Haemorrhagic and non-haemorrhagic adverse reactions 
Tablica 2: Hemoragijske i nehemoragijske nuspojave
It is rapidly hydrolysed in theintestine to a thiolactone, which is then converted to the active metabolite by a single step of cytochrome P450 metabolism, primarily by CYP3A4 and CYP2B6 and to a lesser extent by CYP2C9 
On se u tankom crijevu vrlo brzo hidrolizira u tiolakton, koji se potom u jednom koraku, pomoću citokroma P450 - pretežito CYP3A4 i CYP2B6, a u manjoj mjeri CYP2C9 i CYP2C19 - pretvara u aktivni metabolit.
Prasugrel should be used with caution in patients ≥75 years of age due to the potential risk of bleeding in this population (see sections 4.2 and 4.4). 
Prasugrel treba primjenjivati uz oprez u bolesnika u dobi od ≥ 75 godina zbog mogućeg rizika od krvarenja u ovoj populaciji (vidjeti dijelove 4.2 i 4.4).
Driving and using machines Prasugrel Mylan is unlikely to affect your ability to drive or use machines. 
Nije vjerojatno da bi Prasugrel Mylan mogao utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
• clopidogrel (an anti-platelet agent), 
• klopidogrelom (antitrombocitni lijek)
If you stop taking Prasugrel Mylan 
Ako prestanete uzimati Prasugrel Mylan
Patients ≥75 years old or those below 60 kg (N=3022) were randomized to 5 mg prasugrel. 
Bolesnici u dobi od ≥ 75 godina ili oni čija je tjelesna težina manja od 60 kg (N = 3022) randomizirani su u skupinu koja je primala prasugrel u dozi od 5 mg.
Stroke is an uncommon side effect of Prasugrel Mylan in patients who have never had a stroke or transient ischaemic attack (TIA). 
Moždani udar je manje česta nuspojava lijeka Prasugrel Mylan u bolesnika koji ranije nisu imali moždani udar ni tranzitornu ishemijsku ataku (TIA).
28 film-coated tablets 30 film-coated tablets 30 x 1 film-coated tablets 84 film-coated tablets 90 film-coated tablets 90 x 1 film-coated tablets 98 film-coated tablets 
28 filmom obloženih tableta 30 filmom obloženih tableta 30 x 1 filmom obloženih tableta 84 filmom obložene tablete 90 filmom obloženih tableta 90 x 1 filmom obloženih tableta 98 filmom obloženih tableta
For patients who received their thienopyridine within 3 days prior to CABG, the frequencies of TIMI major or minor bleeding were 26.7% (12 of 45 patients) in the prasugrel group, compared with 5.0% (3 of 60 patients) in the clopidogrel group. 
Među bolesnicima koji su primili tienopiridin unutar 3 dana prije CABG-a, učestalost značajnih ili manjih krvarenja prema TIMI kriterijima iznosila je 26,7% (12 od 45 bolesnika) u skupini koja je primala prasugrel u usporedbi s 5,0% (3 od 60 bolesnika) u skupini koja je primala klopidogrel.
18 months. 
6.3 Rok valjanosti 18 mjeseci
In patients with acute coronary syndrome (ACS) who are managed with PCI, premature discontinuation of any antiplatelet agent, including Prasugrel Mylan, could result in an increased risk of thrombosis, myocardial infarction or death due to the patient's underlying disease. 
U bolesnika s akutnim koronarnim sindromom (engl. acute coronary syndrome, ACS) podvrgnutih PCI-ju, prerani prekid primjene bilo kojeg antitrombocitnog lijeka, uključujući Prasugrel Mylan, može povećati rizik od tromboze, infarkta miokarda ili smrti kao komplikacije bolesnikove osnovne bolesti.
No dose adjustment is necessary for patients with mild to moderate impaired hepatic function (Child Pugh Class A and B). 
Nije potrebno prilagođavati dozu u osoba s blagim do umjerenim oštećenjem jetrene funkcije (ChildPugh stadij A i B).
All of the above may be signs of bleeding, the most common side effect with Prasugrel Mylan. 
Sve to mogu biti znakovi krvarenja, koje je najčešća nuspojava liječenja lijekom Prasugrel Mylan.
The use of Prasugrel Mylan in patients ≥75 years of age is generally not recommended. 
Primjena lijeka Prasugrel Mylan općenito se ne preporučuje u bolesnika u dobi od ≥ 75 godina.
Daily co administration of ranitidine (an H2 blocker) or lansoprazole (a proton pump inhibitor) did not change the prasugrel active metabolite's AUC and Tmax, but decreased the Cmax by 14% and 29%, respectively. 
Svakodnevna istodobna primjena ranitidina (blokatora H2 receptora) odnosno lanzoprazola (inhibitora protonske pumpe) s prasugrelom nije dovela do promjene AUC-a i Tmax, ali je snizila njegov Cmax za 14% odnosno 29%.
Blister packs only: Do not store above 30°C. 
Samo za pakiranja s blisterom: Ne čuvati na temperaturi iznad 30°C.
White opaque HDPE bottle closed with white opaque polypropylene screw cap and aluminium induction sealing liner wad. 
Bijela neprozirna bočica od polietilena visoke gustoće (HDPE) zatvorena zaštitnim aluminijskim pokrovom, s bijelim neprozirnim polipropilenskim navojnim čepom.
Symptomatic ICHd Requiring inotropes Requiring surgical intervention Requiring transfusion (≥4 units) TIMI Minor bleedinge a Other standard therapies were used as appropriate. 
Značajno krvarenje prema TIMIb životno ugrožavajućec smrtonosno simptomatsko IKKd potrebna primjena inotropnih lijekova potrebna kirurška intervencija potrebna transfuzija (≥ 4 jedinice) Manje krvarenje prema TIMIe a Druge standardne terapije primijenjene su po potrebi.
In patients ≥60 kg and age <75 years, non-CABG-related TIMI major or minor bleeding rates were 3.6% for prasugrel and 2.8% for clopidogrel; rates for fatal bleeding were 0.2% for prasugrel and 0.1% for clopidogrel. 
U bolesnika tjelesne težine ≥ 60 kg i mlađih od 75 godina, stopa značajnih ili manjih krvarenja (prema TIMI kriterijima) nevezanih uz CABG iznosila je 3,6% uz prasugrel te 2,8% uz klopidogrel, dok je stopa smrtonosnih krvarenja bila 0,2% uz prasugrel i 0,1% uz klopidogrel.
Prasugrel Mylan, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI). 
Prasugrel Mylan je u kombinaciji s acetilsalicilatnom kiselinom (ASK) indiciran za sprečavanje aterotrombotskih događaja u odraslih bolesnika s akutnim koronarnim sindromom (tj. nestabilnom anginom, infarktom miokarda bez elevacije ST-spojnice [engl. unstable angina, non-ST segment elevation myocardial infarction, UA/NSTEMI] ili infarktom miokarda s elevacijom ST-spojnice [engl.
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised (see section 4.8). 
Preporučuje se nadzor bolesnika s poznatom alergijom na tienopiridine kako bi se uočili znakovi preosjetljivosti (vidjeti dio 4.8).
Non-Coronary Artery Bypass Graft (CABG) related bleeding 
Krvarenja nevezana uz premosnice koronarnih arterija (CABG)
In TRITON, for every 1000 patients treated with prasugrel, there were 22 fewer patients with myocardial infarction, and 5 more with non-CABG-related TIMI major haemorrhages, compared with patients treated with clopidogrel. 
U ispitivanju TRITON je na svakih 1000 bolesnika liječenih prasugrelom broj bolesnika s infarktom miokarda bio manji za 22, dok se broj onih sa značajnim krvarenjem (prema TIMI) nevezanim uz CABG povećao za 5 u usporedbi s bolesnicima liječenima klopidogrelom.
Do not eat or remove the desiccant contained in the bottle Not all pack sizes may be marketed. 
Nemojte gutati niti uklanjati sredstvo za sušenje koje se nalazi u bočici.
Prasugrel should be used with caution in patients with a body weight of <60 kg due to the potential risk of bleeding in this population (see section 4.4). 
Prasugrel treba primjenjivati uz oprez u bolesnika tjelesne težine manje od 60 kg zbog mogućeg rizika od krvarenja u ovoj populaciji (vidjeti dio 4.4).
≥75 years (N=2060)** 
≥ 75 godina (N = 2060)**
Other medicines and Prasugrel Mylan 
Drugi lijekovi i Prasugrel Mylan
◦ If, after a careful individual benefit/risk evaluation by the prescribing physician, treatment is deemed necessary in the ≥75 years age group then following a loading dose of 60 mg, a reduced maintenance dose of 5 mg should be prescribed. 
◦ ako nakon pažljive procjene koristi i rizika u svakog pojedinog bolesnika liječnik propisivač ocijeni da je primjena ovog lijeka neophodna u bolesnika u dobnoj skupini ≥ 75 godina, tada se nakon udarne doze od 60 mg mora propisati niža doza održavanja od 5 mg.
Patients ≥75 years in whom the benefit with prasugrel was more evident included those with diabetes, STEMI, higher risk of stent thrombosis, or recurrent events. 
Korist od primjene prasugrela bila je primjetnija u bolesnika u dobi od ≥ 75 godina koji su imali šećernu bolest, STEMI, povećan rizik od tromboze stenta te onih u kojih su se kardiovaskularni događaji ponavljali.
Prasugrel Mylan 10 mg: microcrystalline cellulose, mannitol, crospovidone, silica colloidal anhydrous, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide (E171), glyceryl monocaprylocaprate, sodium lauryl sulfate, iron oxide yellow (E172), sunset yellow FCF aluminium lake (E110) (see section 2, ‘Prasugrel Mylan 10 mg contains sunset yellow FCF aluminium lake'), iron oxide red (E172). 
Prasugrel Mylan 10 mg: mikrokristalična celuloza, manitol, krospovidon, koloidni bezvodni silicijev dioksid, magnezijev stearat, poli(vinilni alkohol), talk, titanijev dioksid (E171), glicerolkaprilokaprat, natrijev laurilsulfat, žuti željezov oksid (E172), sunset yellow FCF aluminium lake (E110) (vidjeti dio 2, „Prasugrel Mylan 10 mg sadrži sunset yellow FCF aluminium lake”), crveni željezov oksid (E172).
* TRITON study in ACS patients undergoing PCI ** TRILOGY-ACS study in patients not undergoing PCI (see 5.1): a 10 mg prasugrel; 5 mg prasugrel if ≥75 years of age 
* Ispitivanje TRITON provedeno u bolesnika s ACS-om koji su podvrgnuti PCI-ju ** Ispitivanje TRILOGY-ACS u bolesnika koji nisu podvrgnuti PCI-ju (vidjeti dio 5.1): a 10 mg prasugrela; 5 mg prasugrela ako je dob ≥ 75 godina
Prasugrel Mylan 5 mg: microcrystalline cellulose, mannitol, crospovidone, silica colloidal anhydrous, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide (E171), glyceryl monocaprylocaprate, sodium lauryl sulfate, iron oxide yellow (E172). 
Prasugrel Mylan 5 mg: mikrokristalična celuloza, manitol, krospovidon, koloidni bezvodni silicijev dioksid, magnezijev stearat, poli(vinilni alkohol), talk, titanijev dioksid (E171), glicerolkaprilokaprat, natrijev laurilsulfat, žuti željezov oksid (E172).
Prasugrel Mylan inhibits the clumping of platelets and so reduces the chance of a blood clot forming. 
Prasugrel Mylan sprečava nakupljanje trombocita te tako smanjuje vjerojatnost nastanka krvnog ugruška.
The efficacy of prasugrel was independent of the ASA dose (75 mg to 325 mg once daily). 
Djelotvornost prasugrela nije ovisila o dozi ASK-a (75 - 325 mg jedanput na dan).
Non-fatal stroke 
nesmrtonosni moždani udar
If, after a careful individual benefit/risk evaluation by the prescribing physician (see section 4.4), treatment is deemed necessary in the patients age group ≥75 years, then following a 60 mg loading dose a reduced maintenance dose of 5 mg should be prescribed. 
Ako nakon pažljive procjene koristi i rizika u svakog pojedinog bolesnika liječnik propisivač (vidjeti dio 4.4) ipak ocijeni da je primjena ovog lijeka neophodna u bolesnika u dobnoj skupini ≥ 75 godina, tada se nakon udarne doze od 60 mg mora propisati niža doza održavanja od 5 mg.
This medicine is available in plastic bottles containing a desiccant and 28 or 30 film-coated tablets and in blister packs containing 28, 30, 84, 90, 98 and in perforated blister packs containing 30 x 1 and 90 x 1 film-coated tablets. 
Ovaj je lijek dostupan u plastičnim bočicama sa sredstvom za sušenje koje sadrže 28 ili 30 filmom obloženih tableta te u blister pakiranjima koja sadrže 28, 30, 84, 90, 98 filmom obloženih tableta i pakiranjima s perforiranim blisterima koji sadrže 30 x 1 i 90 x 1 filmom obloženih tableta.
Prasugrel Mylan should be initiated with a single 60 mg loading dose and then continued at 10 mg once a day. 
Liječenje lijekom Prasugrel Mylan treba započeti jednokratnom udarnom dozom od 60 mg, a zatim nastaviti s 10 mg jedanput na dan.
The reduction in stent thrombosis with prasugrel was observed both early and beyond 30 days for both bare metal and drug eluting stents. 
Smanjenje broja tromboza stenta kod primjene prasugrela opaženo je i u ranoj fazi liječenja kao nakon više od 30 dana, a odnosilo se kako na čiste metalne tako i na stentove koji izlučuju lijek.
In TRITON, the frequency of patients experiencing a non-CABG related bleeding event is shown in Table 1. 
Učestalost bolesnika u kojih je u ispitivanju TRITON došlo do krvarenja nevezanog uz CABG prikazana je u Tablici 1.
Patients with acute coronary syndromes undergoing PCI treated with prasugrel and ASA showed an increased risk of major and minor bleeding according to the TIMI classification system. 
Bolesnici s akutnim koronarnim sindromom podvrgnuti PCI-ju koji su bili liječeni prasugrelom i ASKom imali su povećan rizik kako od značajnih tako i od manjih krvarenja prema TIMI klasifikaciji.